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Aim: To investigate durability of efﬁcacy and safety over 1 year of the sequence of liraglutide added to
metformin followed by add-on insulin detemir if glycated hemoglobin (HbA1c) remains ≥7.0%.
Methods: Patients previously uncontrolled on metformin ± sulfonylurea with HbA1c≥7.0% after 12 weeks of
adding liraglutide 1.8 mg to metformin (run-in; sulfonylurea discontinued) were randomized 1:1 to
52 weeks’ open-label add-on detemir (randomized treatment [RT] group; n = 162) or continuation without
detemir (randomized control [RC] group; n = 161). Patients with HbA1c b7.0% continued 52 weeks’
unchanged treatment (observational group; n = 498).
Results: Run-in HbA1c improvement from 8.3% to 7.6% (–0.6%) was further enhanced in the RT group (–0.50%)
and maintained in the RC group (+0.01%) over 52 weeks; estimated treatment difference (ETD)[95%CI]:
−0.51 [−0.70;−0.31]; P b 0.0001. More RT (52%) than RC patients (22%) achieved HbA1c b7.0% at 52 weeks
(P b 0.0001). Run-in weight loss (–3.5 kg) wasmaintained in the RT (–0.05 kg) and enhanced in the RC group
(−1.02 kg) after 52 weeks; ETD [95%CI]: 0.97 [0.04;1.91]; P = 0.04. Nomajor hypoglycemia occurred; minor
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Fig. 1. Study design. *Liraglutide initiated at 0.6 mg/da
randomized control group with HbA1c values ≥8.0%, and
with permission from DeVries et al. Diabetes Care 2012
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with sustained weight loss and low hypoglycemia rate.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Metformin is a well-established pharmacologic agent for patients
with type 2 diabetes (T2D) and, contraindications notwithstanding, is
generally the ﬁrst-line treatment of choice (Inzucchi et al., 2012;
Rodbard et al., 2009). Selecting the optimal treatment intensiﬁcation
option(s) for individual patients aftermetformin failure tends tobemore
challenging. The 2012 position statement from the American Diabetes
Association/European Association for the Study of Diabetes (ADA/EASD)
includesgeneral recommendations forﬁve classes of anti-hyperglycemic
agents in second- and third-line treatment combinations (i.e. sulfonyl-
ureas, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4] inhibitors,
glucagon-like peptide-1 receptor agonists [GLP-1RAs], and basal
insulin), albeit without prioritization due, in the authors’ view, to
limited comparative effectiveness data (Inzucchi et al., 2012). Certainly,
diabetes clinical trials are typically conducted in selected populations
and controlled conditions, with study designs based primarily on
meeting regulatory requirements (Inzucchi et al., 2012). Thus, more
translational trials prospectively testing different treatment sequences
in a randomized design are needed. Here, we present data fromone such
translational trial, which examines the efﬁcacy and safety of one
particular intensiﬁcation sequence – the addition of a GLP-1RA
(liraglutide) to metformin for 12 weeks (run-in) (approximately one-
third discontinued sulfonylureas at inclusion), followed by randomiza-
tion of patients with glycated hemoglobin (HbA1c)≥7.0% after run-in to
either further addition of a basal insulin (insulin detemir) or continued
metformin + liraglutide treatment.Wepreviously published the results
observed 26 weeks after randomization (DeVries et al., 2012). Now, we
describe the results of pre-speciﬁed analyses 52 weeks after random-
ization (i.e. the main 26-week treatment period plus the pre-speciﬁed
26-week extension) to assess the durability of glucose-lowering effects
and weight loss, and also the longer-term safety of this intensiﬁcation
treatment sequence. To our knowledge, this is the ﬁrst longer-term
investigation of sequential combination therapy with a once-daily GLP-
1RA and basal insulin in T2D.y and titrated in weekly incremen
giving consent, could intensify trea
;35:1446–54.2. Materials and methods
2.1. Study design and patients
Details of study design and patients enrolled have been reported
previously (DeVries et al., 2012). In brief, this multinational study
investigated the efﬁcacy and safety of an antihyperglycemic
treatment intensiﬁcation sequence in insulin naïve T2D patients. At
study start, patients had been receiving metformin (≥1500 mg/day
for ≥3 months; HbA1c 7.0–10.0%) or metformin (≥1500 mg/
day) + sulfonylurea (≤half maximum approved dose; HbA1c 7.0–
8.5%). In the run-in, sulfonylureas were discontinued and metfor-
min + liraglutide 1.8 mg administered for 12 weeks. Patients with
HbA1c ≥7.0% at the end of run-in were randomly allocated to either
continued metformin + liraglutide 1.8 mg (randomized control [RC]
group) or metformin + liraglutide 1.8 mg + insulin detemir (ran-
domized treatment [RT] group) (Fig. 1). Patients with HbA1c b7.0% at
run-in end continued treatment with metformin + liraglutide
1.8 mg as an observational group. The subsequent main treatment
period (weeks 0–26) corresponded to the assessment of the primary
endpoint (change in HbA1c); the primary endpoint and supporting
efﬁcacy and safety data for this period were reported previously
(DeVries et al., 2012). In a pre-deﬁned extension, patients continued
treatment for a further 26 weeks (no separate re-enrollment step)
except that, for ethical reasons, patients in the RC and observational
groups with HbA1c ≥8.0% at weeks 26 or 38 could opt to intensify
treatment with insulin detemir (in which case, data from the last
visit before intensiﬁcation were carried forward). The study started
(beginning of run-in) on March 3, 2009 and completed on
November 1, 2010. Protocol amendments are noted in the
Supplementary Appendix. Protocol, amendments, and informed
consent documents were approved by independent local ethics
committees and implemented according to Good Clinical Practice
and the Declaration of Helsinki. The trial is registered with
ClinicalTrials.gov (NCT00856986).ts of 0.6 mg/day to ﬁnal dose of 1.8 mg/day; †patients in the observational and the
tment with IDet. IDet, insulin detemir. ©2012 American Diabetes Association; adapted
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The pre-speciﬁed primary outcome (change from randomization
[week 0] to week 26) was reported previously (DeVries et al., 2012).
Efﬁcacy outcomes for the extension study reported here comprised:
changes from randomization to week 52 in HbA1c, fasting plasma
glucose (FPG), postprandial plasma glucose (PPG) from self-measured
seven-point plasma glucose (PG) proﬁles, body weight, blood
pressure (BP), and lipids; proportions of patients at week 52 reaching
HbA1c b7.0% and ≤6.5% and the composite endpoint of HbA1c b7.0%Fig. 2. Flow of patients through the study. *Full details of patient withdrawals during screeni
2012); †Patients with HbA1c ≥8.0% and giving consent at weeks 26/38 intensiﬁed treat
metformin + liraglutide control group received the wrong treatment: onewas supplied with
have been randomized as her glycated hemoglobin level at week 0 was b7.0%. For efﬁcacy an
safety analyses, their data were analyzed according to treatment received. ©2012 Americ
2012;35:1446–54.without weight gain and major or minor hypoglycemia (i.e. no
hypoglycemia during weeks 0–52). Minor hypoglycemic episodes
were deﬁned as those with a conﬁrmed PG b3.1 mmol/l and were
self-treated; major hypoglycemia required third-party assistance,
irrespective of PG level. Pre-speciﬁed safety outcomes included
adverse events (AEs), hypoglycemic episodes, vital signs, and
biochemical and hematological measures. Serum samples were tested
for liraglutide antibodies at weeks –12 (run-in start), 0, 26, 52, and 53
for all patients and positive samples were characterized in vitro for
cross-reactivity to native GLP-1 as described previously (Buse, Garber,ng, run-in and the 26-week main period have been published previously (DeVries et al.,
ment with insulin detemir. Two patients who had been randomly allocated to the
insulin detemir but withdrew before administering the treatment; the other should not
alyses, data for these patients appear in the group to which they were randomized; for
an Diabetes Association; adapted with permission from DeVries et al. Diabetes Care
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insulin detemir and antibodies cross-reacting to human insulin
(Bartley, Bogoev, Larsen, & Philotheou, 2008) at week 0 in all patients,
and at weeks 26, 52, and 53 in patients receiving insulin detemir. The
neutralizing effect of liraglutide and insulin antibodies was evaluated
using scatter plots of antibody response vs. change in HbA1c.
The full analysis set (all randomized patients with at least one
efﬁcacy value) was used for efﬁcacy parameters, unless noted
otherwise, with missing values imputed (last observation forward
[LOCF]). As noted earlier, for observational/RC-group patients inten-
sifying treatment with insulin detemir during the extension, pre-
intensiﬁcation values were carried forward (i.e. LOCF). Statistical
analyses on efﬁcacy parameters were conducted for RT and RC groups
only. Changes from randomization to week 52 were analyzed using an
ANCOVA model with treatment, country, and previous oral antidia-
betic (OAD) therapy as ﬁxed effects and randomization (week 0)
value as covariate. Proportions of patients reaching HbA1c b7% or
≤6.5% were analyzed by logistic regression with treatment and
previous OAD therapy as ﬁxed effects and randomization HbA1c value
as covariate. The logistic regression model used for the composite
endpoint included treatment, country, and previous OAD therapy as
ﬁxed effects and randomization HbA1c and weight values as
covariates. All tests were two-sided with 5% signiﬁcance level and
with no adjustment applied for multiplicity. The safety analysis set
comprised all patients exposed to at least one dose of trial drug. AEs
were included in the treatment group to which patients belonged
when the AE occurred; AEs that increased in severity after
intensiﬁcation were included in both groups. Hypoglycemic episodes
were analyzed using a generalized linear model. Descriptive statistics
were calculated for other safety data from randomized groups and for
all efﬁcacy and safety data from the observational group.
3. Results
3.1. Patient characteristics: randomized and observational groups
Information regarding patient ﬂow through screening, run-in, and
the 26-week main treatment period was published previously
(DeVries et al., 2012) and is outlined in Fig. 2 alongside patient ﬂow
through the 26-week extension. In brief, of 821 patients completingTable 1
Demographics and disease characteristics at run-in start (week –12) and randomization (w
Randomized treatment group
(metformin + liraglutide 1.8 mg +
insulin detemir)
(n = 162)
At run-in (week –12)
Age (years) 56.8 ± 9.4
Male:female (%) 54.3:45.7
BMI (kg/m2) 34.9 ± 6.3
Weight (kg) 99.5 ± 21.2
Duration of diabetes (years) 8.6 ± 5.8
Previous treatment (metformin:
metformin + sulfonylurea)
50.0:50.0
HbA1c (%) 8.2 ± 0.7
Fasting plasma glucose (mmol/l) 10.2 ± 2.4
HOMA-B 59.0 ± 50.8
Systolic blood pressure (mmHg) 134.0 ± 16.9
Diastolic blood pressure (mmHg) 80.1 ± 9.7
At randomization (week 0)
Weight (kg) 96.0 ± 20.9
HbA1c (%) 7.6 ± 0.6
Fasting plasma glucose (mmol/l) 9.2 ± 1.9
Systolic blood pressure (mmHg) 132.2 ± 16.3
Diastolic blood pressure (mmHg) 79.6 ± 9.8
Data are means ± S.D. unless otherwise noted. Data for patients whose treatment was inte
treatment groups (see also Table S2). BMI, body mass index; HbA1c, glycated hemoglobin; H
Association; reproduced with permission from DeVries et al. Diabetes Care 2012;35:1446–5run-in, 648 (79%) from across the RT, RC, and observational treatment
groups completed 52 weeks’ further therapy (Fig. 2). Overall, 18
patients withdrew between completing the 26-week main treatment
period and starting the extension. A total of 51 patients withdrew
during the extension and 24 patients were transferred to the
intensiﬁcation group during the extension. Demographics and disease
characteristics are shown in Table 1 (DeVries et al., 2012).
3.2. Efﬁcacy: randomized groups
HbA1cdecreased from8.3% to 7.6% (–0.6%) in the randomizedgroups
during the initial 12-week run-in (Fig. 3A). Thereafter, a further
decrease (–0.5%) occurred in the RT group (i.e. with add-on insulin
detemir) up toweek12, afterwhichHbA1c remained relatively stable up
to study end (i.e.week52). In contrast, HbA1cwas relatively stable in the
RC group from randomization (week 0) to study end, conﬁrming
adequate duration of the run-in. The range of HbA1c values also shifted
more over time (towards lower HbA1c levels) for the RT group than RC
group (Figure S1). Mean ± S.E. change in HbA1c from week 0 to week
52was signiﬁcantly greater for the RT group (–0.50% [0.09]) than the RC
group (+0.01 [0.09]; estimated treatmentdifference [ETD],–0.51%; 95%
CI [–0.70; –0.31]; P b 0.0001), and the changes were similar in
magnitude to those for weeks 0–26 (DeVries et al., 2012). At week 52,
signiﬁcantlymore RT thanRCpatients achieved anHbA1cb7.0% (52%vs.
22%, respectively; P b 0.0001) or HbA1c≤6.5% (22% vs. 7%, respectively;
P b 0.0001) (see also Table S1). Proportions of patients achieving HbA1c
targets were slightly higher at week 52 than week 26 (Figure S1).
FPG decreases up to 26 weeks (DeVries et al., 2012) were sustained
in both randomized groups during the extension (Fig. 3B); the mean ±
S.E. reduction fromweek 0 toweek 52 for the RT groupwas signiﬁcantly
greater than that for the RC group (–1.91 [0.21] vs. –0.14 [0.21] mmol/l,
respectively; ETD: –1.77 mmol/l; 95% CI [–2.24; –1.30]; P b 0.0001).
Mean self-measured PG levels decreased between week 0 and week 52
in both randomized groups (Fig. 3C). The mean reductions in
postprandial values were signiﬁcantly greater in the RT group than
the RC group for breakfast (ETD –1.74 mmol/l; 95% CI [–2.32; –1.16];
P b 0.0001) and lunch (ETD –0.63 [–1.21; –0.04]; P = 0.04).
The 3.5-kg weight loss during run-in with metformin + liraglu-
tide 1.8 mg was basically maintained over the subsequent 52 weeks
in the RT group (Fig. 3D). Weight loss continued in the RC group overeek 0).
Randomized control group
(metformin + liraglutide 1.8 mg)
(n = 161)
Observational group
(metformin + liraglutide 1.8 mg)
(n = 498)
57.3 ± 9.8 56.5 ± 9.7
55.3:44.7 56.6:43.4
33.9 ± 6.0 34.4 ± 6.7
98.6 ± 21.3 99.0 ± 20.8
8.5 ± 6.0 6.6 ± 5.7
50.3:49.7 74.5:25.5
8.3 ± 0.8 7.7 ± 0.7
10.3 ± 2.5 9.2 ± 1.8
51.2 ± 34.9 63.7 ± 46.1
135.7 ± 16.8 134.4 ± 15.3
80.8 ± 9.8 81.5 ± 9.2
95.3 ± 21.1 94.7 ± 20.5
7.6 ± 0.7 6.4 ± 0.4
8.8 ± 2.1 7.2 ± 1.3
131.7 ± 14.9 128.9 ± 15.2
80.9 ± 9.4 79.4 ± 9.5
nsiﬁed with insulin detemir during the extension period are included in their original
OMA-B, homeostasis model assessment of beta-cell function. ©2012 American Diabetes
4.
Fig. 3. Glycemic efﬁcacy, body weight and insulin detemir doses. Results from run-in to study end are depicted for (A) glycated hemoglobin (HbA1c) levels, (B) fasting plasma glucose
and (D) change in body weight; data are means ± 2 S.E. from the full analysis set with last observation carried forwards. Figure (C) depicts self-monitored plasma glucose proﬁles
before and after breakfast, lunch, dinner, and at bedtime for the randomized treatment and control groups at weeks 0 and 52; data are means ± 2 S.E. from the full analysis set (no
imputation) and P-values refer to differences between randomized groups in the change in postprandial plasma glucose levels from randomization (week 0) to week 52 for each
meal. Figure (E) depicts mean ± S.E. insulin detemir doses (left ordinate) and mean ± S.E. self-measured fasting plasma glucose levels (right ordinate) during the randomized
period for patients randomly allocated to receive IDet. IDet, insulin detemir; RT: randomized treatment group; RC: randomized control group; O: observational group.
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was signiﬁcantly greater for the RC group than RT group (–1.02 [0.41]
vs. –0.05 [0.42] kg, respectively; ETD: 0.97 kg; 95% CI [0.04; 1.91];
P = 0.04). The proportion of patients achieving the composite
endpoint (HbA1c b 7.0% without weight gain and major or minor
hypoglycemia) at week 52 was greater for the RT group (26%) than RC
group (17%) but the treatment difference was not signiﬁcant (P =
0.06; Table S1). These proportions were nevertheless numerically
increased over those at 26 weeks (DeVries et al., 2012).Mean prescribed insulin doses increased from 10 U at week 0 to
39.5 U (0.41 U/kg) at week 26, and were then stable to study end (42
U [0.45 U/kg] at week 50) (Fig. 3E). Mean self-measured FPG
decreased from 7.9 mmol/l at week 1 to 6.1 mmol/l at week 50. The
titration algorithm was apparently followed, with mean prescribed
insulin doses matching closely to recommended doses (Figure S2).
Lipid proﬁle improvements during the 26-week main period
(DeVries et al., 2012) were generally sustained or enhanced during
weeks 27–52(data not shown). Changes in lipidproﬁles forweeks0–52
Table 2
Patients with adverse events (AEs) during weeks 0–52.
Randomized treatment group
(metformin + liraglutide 1.8 mg +
insulin detemir)
(n = 163)
Randomized control group
(metformin + liraglutide 1.8 mg)
(n = 159)
Observational group
(metformin + liraglutide 1.8 mg)
(n = 499)
Intensiﬁed group§
(metformin + liraglutide
1.8 mg + insulin detemir)
(n = 24)
Serious AEs⁎ 17 (10.4) 10 (6.3) 51 (10.2) 1 (4.2)
Deaths† 0 1 (0.6) 1 (0.2) 0
AEs (of any severity) reported by ≥5% of patients
Nasopharyngitis 32 (19.6) 38 (23.9) 64 (12.8) 3 (12.5)
Diarrhea 21 (12.9) 14 (8.8) 35 (7.0) 1 (4.2)
Increased lipase 20 (12.3) 7 (4.4) 39 (7.8) 4 (16.7)
Headache 13 (8.0) 15 (9.4) 41 (8.2) 2 (8.3)
Upper respiratory tract infection 12 (7.4) 7 (4.4) 21 (4.2) 0
Vomiting 10 (6.1) 9 (5.7) 21 (4.2) 0
Nausea 9 (5.5) 12 (7.5) 25 (5.0) 1 (4.2)
Oropharyngeal pain 4 (2.5) 10 (6.3) 13 (2.6) 0
Back pain 3 (1.8) 8 (5.0) 17 (3.4) 1 (4.2)
Data are number (%) of patients.
⁎ Serious AEs for the extension period are detailed in Table S3; serious AEs for the main 26-week trial period are detailed in DeVries et al., 2012.
† Two deaths occurred in the extension: one death (randomized control group) was due to pulmonary mass and CNSmetastases that had occurred in themain period [see DeVries
et al., 2012]; the other death (observational group) followed a serious AE in the extension (see Table S3).
§ AEs for patients intensifying treatment with insulin detemir during the extension are tabulated with the initial treatment group if the adverse event occurred before
intensiﬁcation; AEs that increased in severity after intensiﬁcation are tabulated in both treatment groups. N/A, not applicable.
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a greater increase in high-density lipoprotein cholesterol levels for the
RTgroup thanRCgroup (0.07 [0.02] vs. 0.02 [0.02]mmol/l, respectively;
ETD: 0.05 mmol/l; 95% CI [0.01; 0.08]; P = 0.01). Decreases from run-
in start to 52 weeks occurred in both randomized groups for mean
systolic BP (SBP) (RT group, –2.07 mmHg; RC group, –4.89 mmHg)
and mean diastolic BP (DBP) (RT group, –0.54 mmHg; RC group,
–1.44 mmHg). Differences between the two randomized groups for
changes in SBP or DBP for weeks 0–52 were not statistically signiﬁcant
(SBP, ETD: 0.90 mmHg, 95%CI [–1.85; 3.64]; P = 0.52; DBP, ETD:
0.77 mmHg [–1.02; 2.55]; P = 0.40).
3.3. Efﬁcacy: observational group
The group comprised patients reaching HbA1c b 7.0% at run-in
end. Fifty-two weeks later, 73% had an HbA1c b7.0%. Over the whole
study, the group experienced a mean change of –1.05% in HbA1c (7.7%
at run-in start; 6.7% at week 52; Fig. 3A). The group also showed
reductions in FPG (–1.8 mmol/l; 9.2 mmol/l at run-in start; 7.4 mmol/
l at week 52), seven-point PG, and weight (–4.7 kg; 99.0 kg at run-in
start; 94.4 kg at week 52) (Figs. 3B–D).
3.4. Intensiﬁed group
Sixty-three patients (RC group, 45/161 [28%]; observational group,
18/498 [4%]) met the criterion for treatment intensiﬁcation (HbA1c
≥8.0%) with insulin detemir during the extension; of these, 24 patients
(RC group, n = 17; observational, n = 7) agreed to intensify treatment
(intensiﬁed group). Compared with the other groups at run-in start
(Table 1), the intensiﬁed group was younger (mean ~2 years younger
than the overall study population), had higher body mass index (BMI)
and weight values (mean weight almost 10 kg higher), and a greater
proportion (58%) were previously treated with metformin + sulfony-
lurea than metformin monotherapy (42%) (Table S2). Reductions were
apparent in HbA1c (mean change from run-in start to week 52, –1.0%
[n = 22]; 8.4% at run-in start to 7.4% at week 52), FPG (–3.33 mmol/l
[n = 21]; from 10.4 mmol/l to 7.1 mmol/l) and weight (–3.86 kg [n =
22]; from 108.6 kg to 101.8 kg at week 52).
3.5. Safety
Similar proportions of RT and observational groups reported at least
one AE over weeks 0–52 (72.4% [n = 118] vs 73.7% [n = 368],respectively); somewhat smaller proportions reported AEs in the
other groups (RC group, 64.2% [n = 102]; intensiﬁed group, 58.3%
[n = 14]). Nasopharyngitis was the most common AE over this period
in randomized and observational groups (12.8–23.9%); increased lipase
levelswas themost commonAE in the intensiﬁed group (16.7%; n = 4;
Table2). Althoughnausea, vomiting, anddiarrheawere reported in≥5%
of patients over weeks 0–52, there was a clear decrease in the
proportions reporting these gastrointestinal symptoms from run-in
start to study end. Thus, nausea frequencies over the run-in ranged from
14.1 to 24.2% across groups (DeVries et al., 2012); these fell to 3.2–5.7%
over the 26-week main period (DeVries et al., 2012) and then to 1.9–
4.2% over the subsequent 26-week extension (see also Figure S3). The
incidence (number of new nausea events) fell to b7% in all groups after
the initial 3 weeks of treatment (DeVries et al., 2012). For vomiting, the
frequencies over run-in, the 26-week main period, and subsequent 26-
week extension for the groups were 5.5–8.0%, 3.0–4.9% (DeVries et al.,
2012), and 0.0–2.5%, respectively. For diarrhea, the frequencies were
6.7–9.8%, 3.8–11.7% (DeVries et al., 2012), and 2.5–4.2%, respectively.
No deaths occurred in weeks 0–26 (DeVries et al., 2012). Two
deaths occurred in weeks 27–52; one was due to gallbladder cancer
with liver metastases (observational group) and one to a pulmonary
mass with central nervous system (CNS) metastases (RCT group;
Table 2, Table S3). The proportion of patients reporting serious AEs
(SAEs) was low in all groups for weeks 0–52 with no observed pattern
or clustering (Table 2).
No major hypoglycemia occurred during weeks 0–52. Minor
hypoglycemia rates were low in all groups (RT group, 0.23 events/
patient-year [33 episodes during 145 patient-years of exposure]; RC
group, 0.03 events/patient-year [4 episodes during 118 patient-
years]; observational group, 0.12 events/patient-year [53 episodes
during 462 patient-years]; intensiﬁed group, 0.10 events/patient-year
[1 episode during 10 patient-years]). Minor hypoglycemia rates were
signiﬁcantly lower for the RC group than the RT group using the pre-
speciﬁed analysis (i.e. excluding one outlier in the RC group with 37
minor and symptoms-only hypoglycemic episodes; rate ratio, 6.80;
95%CI [2.14; 21.60]; P = 0.0011). With outlier included, the differ-
ence between randomized groups was not signiﬁcant.
Four pancreatitis cases occurred during the entire study: one
occurred during run-in and one during weeks 0–26 as described
previously (DeVries et al., 2012; Steinberg et al., 2012); two cases
occurred during the extension (RC group, acute pancreatitis;
observational group, ‘pancreatitis’ [not deﬁned further]). A total of
20.4% (199/977) of patients had lipase values above the upper limit of
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821) had lipase elevations to≥2 × ULN at some point during the trial;
however, only one of these elevations preceded a case of pancreatitis
(observational group). More ‘increased lipase’ AEs were reported in
the RT group than the other groups (Table 2). Minor increases in
median lipase levels (but still remaining below the ULN) were
observed with no apparent difference between groups from run-in to
week 26 (DeVries et al., 2012), followed by no further change or a
trend towards a decrease during weeks 27–52 (Figure S4).
Heart rate increaseswere observed in all groups during run-in (Figure
S5). These were followed by a gradual decrease during weeks 0–52 such
that, at study end, mean heart rates were still increased compared with
run-in start (RT group, 2.80 beats/min; RC group, 2.54 beats/min;
observational group, 2.72 beats/min; intensiﬁed group, 1.27 beats/min).
At the start of run-in, none of the patients had positive tests for
anti-liraglutide antibodies (Table S4). At week 53 (for patients
discontinuing liraglutide at week 52), 21 of the 596 patients tested
(3.5%) had anti-liraglutide antibodies; 20 of these 21 patients showed
GLP-1 cross-reactive effects but only seven (1.2% of patients tested)
showed neutralizing effects. Mean titers for anti-detemir antibodies
were generally low throughout the trial (Table S5), while mean titers
for anti-insulin antibodies cross-reacting to insulin detemir increased
slightly over time. There were no correlations between titer changes
(either speciﬁc to or cross-reacting with insulin detemir) and changes
in HbA1c, and no indication that co-treatment with liraglutide and
insulin detemir inﬂuenced antibody formation.
4. Discussion
Sequential intensiﬁcation of metformin with the long-acting GLP-
1RA liraglutide, followed by 26 weeks of add-on insulin detemir was
previously shown to be safe and efﬁcacious in T2D (DeVries et al., 2012).
The present report provides the ﬁrst longer-term evaluation of the
liraglutide–basal insulin combination. Improvements in glycemic con-
trol and weight reductions were sustained for a further 26 weeks, with
no evidence of declining efﬁcacy, and with low rates of hypoglycemia,
nausea, and other AEs. Co-treatmentwith basal insulin did not affect the
development of anti-liraglutide antibodies or vice versa. The low anti-
liraglutide antibody frequency was, in fact, smaller than previously
observed in liraglutide phase 3 clinical trials (Buse, Garber, et al., 2011)
and there was no adverse effect on glycemic efﬁcacy.
Modest weight gain and an increased risk of mild hypoglycemia
typically accompany basal insulin treatment (Hermansen et al., 2006
Inzucchi et al., 2012; Riddle, Rosenstock, Gerich, & Insulin Glargine 4002
Study Investigators, 2003), such that there may be reluctance to initiate
or intensify insulin therapy (Peyrot, Rubin, & Khunti, 2010). It is
noteworthy that in the present trial, the 3.5-kg mean weight loss with
12 weeks of metformin + liraglutide 1.8 mg was maintained with
52 weeks of add-on insulin detemir. Moreover, although the conﬁrmed
minor hypoglycemia rate reported previously for patients receiving
insulin detemir for 26 weekswas already very low (0.29 events/patient-
year [22 episodes during 77 patient-years of exposure] (DeVries et al.,
2012), the data suggest a slightly lower rate in the 27–52-week period
because the overall 52-week rate was 0.23 events/patient-year (33
episodes during 145 patient-years of exposure). The lower rate during
the extension likely resulted from stabilization of insulin doses during
the previous 26-week treatment period. Minor hypoglycemia rates in
this study also compared favorably with those from other trials with
insulin detemir added to OADs: 1.6 events/patient-year for insulin
detemir + metformin (Swinnen et al., 2010) and 0.52 events/patient-
year for insulindetemir + sitagliptin + metformin (Hollander, Raslova,
Skjoth, Rastam, & Liutkus, 2011). GLP-1RAs may be associated with low
hypoglycemia rates by perhaps preserving pancreatic defenses against
hypoglycemia (Kielgast, Asmar, Madsbad, & Holst, 2010; Nauck et al.,
2002).Moreover, in liraglutide–basal insulin combination therapy, using
liraglutide is likely to reduce the insulin dosage needed to achieve thetarget HbA1c and may mitigate the need for prandial insulin to control
PPG levels at all threemeals. Similar additive effects havebeen shown for
twice-daily exenatide,whichmayhavemore exclusive PPGeffects as it is
administered like a bolus treatment before meals due to its shorter half-
life (2.4 h) (Arnolds et al., 2010; Buse, Bergenstal, et al., 2011). The
longer-term ﬁndings in the present study for weight and hypoglycemia
may reassure those concerned about insulin initiation, andmay facilitate
improved patient adherence to their treatment regimens.
In the RC and observational groups (receivingmetformin + liraglu-
tide 1.8 mg), HbA1c decreases were generally stable after run-in, and
very few patients (28 and 4%, respectively) were eligible for add-on
insulin detemir (i.e. HbA1c ≥8.0% at weeks 26/38). Even though
approximately one-third of patients overall were switching from
metformin + sulfonylurea (rather than adding to previous metformin
monotherapy), HbA1c reductions over the 64-week study ranged from
0.66% to 1.05%. These are comparable to the reduction (0.6%) in another
2-year switch study of patients receiving liraglutide 1.8 mg after failure
of OAD monotherapy or combination therapy (Nauck et al., 2012). As
expected, in a true add-on study, a greater reduction (1.5%) was
observed for metformin + liraglutide 1.8 mg after 52 weeks (Pratley
et al., 2011). Mean weight losses were similar for RC and observational
groups in the present study, although weight loss was achieved more
quickly in the latter group (Fig. 3). Overall weight loss (4.7 kg in both
groups) was greater than observed previously (2.9 kg (Nauck et al.,
2012) and 3.7 kg, respectively (Pratley et al., 2011)), again, likely due to
sulfonylurea termination for many patients.
Sequential intensiﬁcation clearly effected considerable improve-
ments in HbA1c for themajority of patients during the 64-week period
(Figure S1). In fact, extrapolating from data in the present study, we
might predict that approximately 75% of individuals uncontrolled on
metformin ± sulfonylurea in clinical practice could achieve glycemic
control (HbA1c b7.0%) with the stepwise treatment intensiﬁcation
employed here (Figure S6). Importantly, of the patients who had been
receiving metformin + sulfonylurea previously (approximately one-
third), a smaller proportion achieved the HbA1c target compared with
those previously receiving metformin monotherapy (45 vs. 70%,
respectively) (Bain, Seufert, Thomsen, Furber, & D’Alessio, 2010).
While the prediction can apply only to patients with the same clinical
proﬁle as those in the study, the study inclusion criteria do correspond
well with patients encountered in daily clinical practice.
While good glycemic control remains an important goal in T2D, it
remains unclear whether or not even mild hypoglycemia may induce
harm. In a recent large nationwide observational cohort study from
Taiwan, even mild symptomatic hypoglycemia was signiﬁcantly
associated with an increased risk of cardiovascular events, all-cause
hospitalization, and all-cause mortality (Hsu et al., 2012). In addition,
Zhao and colleagues reported recently that patients with hypoglyce-
mia had signiﬁcantly higher risks of cardiovascular events (hazard
ratio, 2.00) and microvascular complications (hazard ratio, 1.76)
(Zhao, Campbell, Fonseca, & Shi, 2012). Hence, physicians need to
carefully balance the risks and beneﬁts of tight glycemic control for
individual patients. In the present study, notwithstanding the absolute
low rates of hypoglycemia with liraglutide + insulin detemir treat-
ment, this RT group did have a higher rate ofminor hypoglycemia than
the RC group. However, comparing the hypoglycemic rates between
the observational and RT groups (with quite similar glycemic levels),
the difference in the absolute risk of hypoglycemia was very small and
probably not clinically relevant, implying that addition of insulin
detemir to liraglutide could be undertaken without an additional
signiﬁcant increase in hypoglycemia risk.
Post-marketing reports of pancreatitis in patients with T2D treated
with incretin therapies (US Food and Drug Administration, 2008,
2009) have prompted routine monitoring of pancreatic enzymes in
clinical trials involving these agents. Elevated pancreatic enzyme
levels (≥3 × ULN) are considered markers of pancreatic inﬂamma-
tion, but are not diagnostic for pancreatitis by themselves (at least two
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characteristic abdominal pain; characteristic ﬁndings of acute pan-
creatitis with contrast-enhanced computed tomography (Banks et al.,
2013)). In the present study, 20.4% of patients had lipase values N ULN
before treatment started and many experienced large serum lipase
ﬂuctuations throughout the trial. In fact, 156 (19.0%) patients
exhibited a lipase elevation to ≥2 x ULN at some time during the
study, but pancreatitis was reported for only one of these patients. The
positive predictive value of lipase elevations ≥2 × upper limit of the
normal range for the diagnosis of acute pancreatitis was thus very low
(b1%), and the cause of lipase ﬂuctuations is presently unknown.
Importantly, in this trial of approximately 900 patient-years of
exposure, the four pancreatitis cases are probably in line with the
background pancreatitis incidence in T2D (~4 cases/1000 patient-
years) (Noel, Braun, Patterson, & Bloomgren, 2009). Moreover, in an
independent post-hoc adjudication of pancreatitis cases occurring
during T2D clinical trials with liraglutide, the majority did not meet
diagnostic criteria (Steinberg et al., 2012). Nevertheless, vigilance for
pancreatitis remains a prudent approach for clinicians prescribing
GLP-1 RAs until a robust answer is hopefully obtained from the large
long-term safety outcomes trials being undertaken with these
compounds (e.g. ClinicalTrials.gov, 2012a [NCT01179048]; (Clinical-
Trials.gov, 2012b [NCT01144338]).
The strengths of the present study include the longer term (N1 year)
investigation period and use of pre-deﬁned protocol endpoints/
analyses. Additionally, the stepwise treatment intensiﬁcation mirrors
the approach used in clinical practice: the addition of a second, typically
non-insulin, anti-hyperglycemic agent aftermetformin failure, followed
by a third-line therapy (in this case, basal insulin) in patients failing to
meet glycemic targets using two-agent combinations. Moreover, with
the particular treatment sequence employed here, patients are able to
adapt to the requirements of a once-daily injectable treatment before
initiating further (insulin) injections. Liraglutide treatmentalsodoesnot
require frequent self-monitoring of bloodglucose and does not carry the
same hypoglycemia risk as prandial insulin therapy. By avoiding the
weight gain usually associated with initiating insulin, improved
treatment compliance and duration of glycemic control might be
anticipated. Trial limitations include the absence of placebo or active
comparators in the RC group. As the ﬁrst investigation of liraglutide in
combination with insulin in T2D, the emphasis was on safety and no
active comparatorwas included.However, as safetywas conﬁrmed tobe
good and the hypoglycemia risk very low, future investigations need to
include an active comparator for higher prioritization of efﬁcacy. A trial
investigating the addition of liraglutide to basal insulin is already
underway (ClinicalTrials.gov, 2012c [NCT01617434]). Studies analyzing
the cost–beneﬁt outcomes could also be very valuable. Ideally, such
studies should include not only medication costs, but also the overall,
long-term savings in medical and hospital costs that may result from a
lower risk of hypoglycemia and potentially a lower risk of complications
associated with sustained treatment adherence and glycemic control.
In summary, intensiﬁcation of metformin treatment with the
once-daily GLP-1RA liraglutide enabled the majority of patients
previously inadequately controlled with metformin ± sulfonylurea
to reach the ADA/EASD target HbA1c of 7.0% after 12 weeks, with
glycemic and weight reductions sustained over the subsequent
52 weeks of continued treatment. Further treatment intensiﬁcation
with insulin detemir for patients with HbA1c remaining ≥7.0% after
12 weeks of metformin + liraglutide 1.8 mg resulted in additional
sustained improvement in glycemic control with a very low
hypoglycemia rate and maintenance of pre-intensiﬁcation weight
reduction over 52 weeks.
Acknowledgments
The authors gratefully acknowledge the contribution of investiga-
tors and their staff and of patients participating in this trial. Theauthors thank Irina Nayvelt, PhD (Novo Nordisk) for medical writing
support, and Watermeadow Medical, funded by Novo Nordisk, for
medical writing and editing support. The trial sponsor participated in
trial design, collection, review, and analysis of data. All authors had
full access to data and had ﬁnal responsibility for manuscript content
and submission.Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jdiacomp.2013.04.008.References
Arnolds, S., Dellweg, S., Clair, J., Dain, M. P., Nauck, M. A., Rave, K., et al. (2010). Further
improvement in postprandial glucose control with addition of exenatide or
sitagliptin to combination therapy with insulin glargine andmetformin: a proof-of-
concept study. Diabetes Care, 33, 1509–1515.
Bain, S. C., Seufert, J., Thomsen, A. B., Furber, S., & D’Alessio, D. (2010). Liraglutide +
metformin in type 2 diabetes: clinical beneﬁts associated with switch or use early
in the disease process. Diabetes, 61(Suppl 1), A301 (abstract 1168-P).
Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., et al.
(2013). Classiﬁcation of acute pancreatitis–2012: revision of the Atlanta classiﬁ-
cation and deﬁnitions by international consensus. Gut, 62, 102–111.
Bartley, P. C., Bogoev, M., Larsen, J., & Philotheou, A. (2008). Long-term efﬁcacy and
safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in
patients with type 1 diabetes using a treat-to-target basal-bolus regimen with
insulin aspart at meals: a 2-year, randomized, controlled trial. Diabetic Medicine, 25,
442–449.
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y., et al.
(2011). Use of twice-daily exenatide in basal insulin-treated patients with type 2
diabetes: a randomized, controlled trial. Annals of Internal Medicine, 154, 103–112.
Buse, J. B., Garber, A., Rosenstock, J., Schmidt, W. E., Brett, J. H., Videbæk, N., et al. (2011).
Liraglutide treatment is associated with a low frequency and magnitude of
antibody formation with no apparent impact on glycemic response or increased
frequency of adverse events: results from the Liraglutide Effect and Action in
Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism, 96,
1695–1702.
ClinicalTrials.gov. (2012a). Liraglutide effect and action in diabetes: evaluation of
cardiovascular outcome results – a long term evaluation (LEADER®)
(NCT01179048) Available from: http://www.clinicaltrials.gov/ct2/show/
NCT01179048 (accessed December 18, 2012).
ClinicalTrials.gov. (2012b). Exenatide study of cardiovascular event lowering trial
(EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with
exenatide once weekly in patients with type 2 diabetes (NCT01144338) Available
from: http://www.clinicaltrials.gov/ct2/show/NCT01144338 (accessed December
18, 2012).
ClinicalTrials.gov. (2012c). The effect of liraglutide versus placebo when added to basal
insulin analogues with or without metformin in subjects with type 2 diabetes
(NCT01617434) Available from: http://clinicaltrials.gov/ct2/show/NCT01617434
(accessed December 18, 2012).
DeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D’Alessio, D., Thomsen, A. B., et al.
(2012). Sequential intensiﬁcation of metformin treatment in type 2 diabetes with
liraglutide followed by randomized addition of basal insulin prompted by A1C
targets. Diabetes Care, 35, 1446–1454.
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., & Home, P. A.
(2006). 26-week, randomized, parallel, treat-to target trial comparing insulin
detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in
insulin naïve people with type 2 diabetes. Diabetes Care, 29, 1269–1274.
Hollander, P., Raslova, K., Skjoth, T. V., Rastam, J., & Liutkus, J. F. (2011). Efﬁcacy and safety
of insulin detemir once daily in combination with sitagliptin and metformin: the
TRANSITION randomized controlled trial.Diabetes, Obesity&Metabolism, 13, 268–275.
Hsu, P. F., Sung, S. H., Cheng, H. M., Yeh, J. S., Liu, W. L., Chan, W. L., et al. (2012).
Association of clinical symptomatic hypoglycemia with cardiovascular events and
total mortality in type 2 diabetes mellitus: a nationwide population-based study.
Diabetes Care, 36, 894–900.
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., et al.
(2012). Management of hyperglycaemia in type 2 diabetes: a patient-centered
approach. Position statement of the American Diabetes Association (ADA) and the
European Association for the Study of Diabetes (EASD). Diabetologia, 55,
1577–1596.
Kielgast, U., Asmar, M., Madsbad, S., & Holst, J. J. (2010). Effect of glucagon-like peptide-
1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients.
Journal of Clinical Endocrinology and Metabolism, 95, 2492–2496.
Nauck, M., Frid, A., Hermansen, K., Thomsen, A. B., During, M., Shah, N., et al. (2012). Long-
term efﬁcacy and safety comparison of liraglutide, glimepiride, and placebo, all in
combinationwithmetformin in type 2diabetes: 2-year results fromthe LEAD-2 study.
Diabetes, Obesity & Metabolism, 15, 204–212.
Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., et al. (2002).
Effects of glucagon-like peptide 1 on counterregulatory hormone responses,
cognitive functions, and insulin secretion during hyperinsulinemic, stepped
500 J. Rosenstock et al. / Journal of Diabetes and Its Complications 27 (2013) 492–500hypoglycemic clamp experiments in healthy volunteers. Journal of Clinical
Endocrinology and Metabolism, 87, 1239–1246.
Noel, R. A., Braun, D. K., Patterson, R. E., & Bloomgren, G. L. (2009). Increased risk of
acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a
retrospective cohort study. Diabetes Care, 32, 834–838.
Peyrot, M., Rubin, R. R., & Khunti, K. (2010). Addressing barriers to initiation of insulin in
patients with type 2 diabetes. Primary Care Diabetes, 4(Suppl 1), S11–S18.
Pratley, R., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., et al. (2011). One
year of liraglutide treatment offers sustained and more effective glycaemic control
and weight reduction compared with sitagliptin, both in combination with
metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-
label trial. International Journal of Clinical Practice, 65, 397–407.
Riddle, M. C., Rosenstock, J., Gerich, J., & Insulin Glargine 4002 Study Investigators
(2003). The treat-to-target trial: randomized addition of glargine or human NPH
insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 26, 3080–3086.
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G.,
et al. (2009). Statement by an American Association of Clinical Endocrinologist-
s/American College of Endocrinology consensus panel on type 2 diabetes mellitus:
an algorithm for glycemic control. Endocrine Practice, 15, 540–559.Steinberg, W., DeVries, J. H., Wadden, T., Jensen, C. B., Svendsen, C. B., Rosenstock, J.,
et al. (2012). Longitudinal monitoring of lipase and amylase in adults with type 2
diabetes and obesity: evidence from two phase 3 randomized clinical trials with the
once-daily GLP-1 analog liraglutide. Gastroenterology, 142(Suppl 1), S850–S851.
Swinnen, S. G., Dain, M. P., Mauricio, D., DeVries, J. H., Hoekstra, J. B., & Holleman, F.
(2010). Continuation versus discontinuation of insulin secretagogues when
initiating insulin in type 2 diabetes. Diabetes, Obesity & Metabolism, 12, 923–925.
US Food and Drug Administration. (2008). Information for healthcare professionals –
exenatide (marketed as Byetta). http://www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm
(accessed December 18, 2012).
USFood andDrugAdministration. (2009). Information for healthcareprofessionals– acute
pancreatitis and sitagliptin (marketed as Januvia and Janumet). http://www.fda.gov/
Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/
DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm (accessed De-
cember 18, 2012).
Zhao, Y., Campbell, C. R., Fonseca, V., & Shi, L. (2012). Impact of hypoglycaemia
associated with antihyperglycemic medications on vascular risks in veterans with
type 2 diabetes. Diabetes Care, 35, 1126–1132.
